TESARO (TSRO) Lower Following Negative Report
- Record-setting rally pushes on as S&P ends week up 3 percent
- Trump's Cohn Pick Most Bullish Sign Yet for Banks - Cowen
- Unusual 11 Mid-Day Movers: (IDXG) (INVN) (EBS) Higher; (SCON) (DTEA) (DLTH) Lower (more...)
- 21st Century Fox (FOXA) offers to acquire Sky for GBP10.75/share
- Coca Cola (KO) Announces James Quincey to Succeed Muhtar Kent as CEO; Kent to Continue as Chairman
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
TESARO (NASDAQ: TSRO) is weak Tuesday following a negative research reports from Favus. The firm sees downside risk and notes Clovis Oncology, Inc. (NASDAQ: CLVS) data may pressure the stock. Shares of TSRO are down 5%.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mizuho Discusses Biogen (BIIB) Seizure Patient
- New Bill Suggests GSE Reform is Forthcoming (FNMA) (FMCC)
- BMO Capital Cuts Price Target on Cooper Cos. (COO) Following 4Q Results
Create E-mail Alert Related CategoriesAnalyst Comments, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!